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Abstract
Background. The current study was performed to
investigate the kinetics of carnitine, individual acylcar-
nitines and butyrobetaine in patients on haemodialysis.
Methods. Eight stable long-term haemodialysis
patients were studied under basal conditions (no
carnitine supplementation) and 3 weeks after intrave-
nous supplementation with L-carnitine (10 or 20mg/kg
body weight) after each haemodialysis session. The
kinetic studies included serial determinations of carni-
tine and metabolites just before, during or between
haemodialysis sessions. Analysis was performed by
liquid chromatography–tandem mass spectrometry.
Results. Before haemodialysis, the plasma concentra-
tions were (mmol/l) 15.1±0.6 (mean±SEM) for
carnitine, 5.9±0.7 for acetylcarnitine, 0.66±0.04 for
propionylcarnitine and 0.98±0.08 for butyrobetaine
(basal conditions) or 142±23 for carnitine, 69±12
for acetylcarnitine, 6.0±1.1 for propionylcarnitine
and 2.6±0.3 for butyrobetaine (carnitine 20mg/kg).
During haemodialysis, the plasma concentrations
dropped by 80% for all compounds determined,
with extraction coefﬁcients ranging from 0.65 to 0.86.
In patients supplemented with 20mg/kg carnitine, the
amount of carnitine removed by haemodialysis
equalled 42% of the dose administered, consisting of
2.08mmol carnitine, 1.03mmol acetylcarnitine and
0.051mmol propionylcarnitine. Between the haemo-
dialysis sessions, carnitine, acylcarnitines and butyro-
betaine reached apparent steady-state concentrations
within 1 day both under basal conditions and after
supplementation.
Conclusions. Patients on haemodialysis have reduced
carnitine, acylcarnitine and butyrobetaine plasma
levels, which can be increased by supplementing
carnitine. Propionylcarnitine, an important constituent
of the acylcarnitine pool, can be removed by haemo-
dialysis. Removal of potentially toxic acyl-groups
may represent a mechanism for a beneﬁcial effect of
carnitine in these patients.
Keywords: acylcarnitines; butyrobetaine; carnitine;
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Introduction
Carnitine (L-3-hydroxy-4-N-trimethylaminobutyrate),
an endogenous compound present in most mammalian
tissues, is ingested by the diet and produced endo-
genously by biosynthesis. Carnitine is an essential factor
for transport of long-chain fatty acids into the
mitochondrial matrix, where they are metabolized via
b-oxidation [1]. By reacting with activated fatty acids,
carnitine can generate various acylcarnitines with
different chain lengths. By accepting acyl-groups from
acyl-CoAs, carnitine is also involved in the regulation of
the cellular pool of free coenzyme A (CoASH), thus
acting as a buffer [1]. This buffer effect of carnitine may
be important for the detoxiﬁcation and elimination of
potentially toxic acyl-groups, originating from exposure
to xenobiotics and/or from blockage of metabolic
pathways. In contrast to acyl-CoAs, the corresponding
acylcarnitines can be excreted in the urine [1,2].
In healthy subjects, carnitine and acetylcarnitine
represent the major constituents of the body ﬂuid and
tissue carnitine pools [1,3]. Skeletal muscle contains
>95% of the total carnitine body stores and the tissue
concentrations are considerably higher than the con-
centration in plasma, necessitating active transport into
tissues. Kidneys play a crucial role in carnitine homeo-
stasis, since they reabsorb >90% of the ﬁltered
carnitine [1], so that the plasma levels of free carnitine
are maintained at 30–40 mmol/l [4,5].
Since carnitine is a small molecule (molecular weight:
161.2) and not protein-bound, it is efﬁciently removed
Correspondence and offprint requests to: Stephan Kra¨henbu¨hl,
Division of Clinical Pharmacology and Toxicology, University
Hospital, CH-4031 Basel, Switzerland.
Email: kraehenbuehl@uhbs.ch
 The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
For Permissions, please email: journals.permissions@oxfordjournals.org
from blood through dialyser membranes [1]. Patients
with end-stage renal disease undergoing long-term
haemodialysis, therefore, have reduced carnitine
plasma [6–8] and muscle levels [7,8] and may exhibit
symptoms similar to those observed in patients with
carnitine deﬁciency, e.g. skeletal muscle weakness and
pain as well as impaired exercise performance [1]. In
addition, such patients may suffer from intradialytic
cramps and hypotensive episodes, which may also be
related to low carnitine tissue stores [1]. In plasma of
patients with haemodialysis, the carnitine concentration
has been found to be decreased and the acylcarnitine
concentration to be increased, so that the acylcarnitine
to total carnitine ratio (free carnitine plus acylcarni-
tines) is higher than in healthy subjects [6,8].
Supplementation with carnitine, either orally or
intravenously, at the end of haemodialysis has been
shown to increase the carnitine plasma concentration
[6,9] and carnitine skeletal muscle content [9]. Despite
the fact that carnitine supplementation is clearly
associated with an increase in carnitine plasma and
tissue levels, carnitine administration has been shown
to be associated with clinical improvement of muscular
symptoms in some [7,10] but not all studies or patients
[11]. In order to answer the question whether the
administration of carnitine is beneﬁcial to patients with
haemodialysis, larger placebo-controlled studies with
relevant clinical endpoints would be needed.
In several studies, the metabolism of carnitine in
patients on long-term haemodialysis has been investi-
gated. Most of them were restricted to the observation
of free and acylcarnitines [12,13], but in some studies the
individual acylcarnitines were differentiated [6,14]. In
one recent study, the plasma concentration of carnitine,
acetylcarnitine and total carnitine was investigated in
patients on haemodialysis before and after intravenous
supplementation of different doses of carnitine [6].
In the current study, we investigated the composition
of the plasma carnitine, acylcarnitine and butyro-
betaine pools in patients on long-term haemodialysis
under baseline conditions and during intravenous
supplementation with two different doses of carnitine.
The kinetics of carnitine, individual acylcarnitines and
butyrobetaine were evaluated during and between
haemodialysis sessions. The analytical method utilized
was high-performance liquid chromatography–tandem
mass spectrometry (HPLC–MS/MS) [5], which allows
the quantiﬁcation of all analytes mentioned above. We
were particularly interested to determine which acyl-
carnitines other than acetylcarnitine accumulate in the
plasma of patients on long-term haemodialysis and
how the plasma butyrobetaine pool is inﬂuenced by the
administration of carnitine.
Subjects and methods
The study was approved by the Ethics Committee of the
Cantons of Basel and patients provided written informed
consent before the start of the study.
Study population
Patients aged between 20 and 80 years were recruited at the
dialysis centre of the University Hospital of Basel. Enrolment
requirements included treatment with haemodialysis three
times a week for>6months and the absence of acute illnesses.
Patients already supplemented with carnitine, either orally or
intravenously, were also excluded from the study.
Eight patients (four women and four men) with a mean age
of 59 years (Table 1) were included. They underwent three
dialysis sessions per week, each of them having a duration of
240min. The dialysate ﬂuid was based on bicarbonate (not
acetate) and the dialysate ﬂow was kept constant at 0.5 l/min.
An HF 80 dialysis membrane (Fresenius, Bad Homburg,
Germany), the most commonly used membrane in our
haemodialysis centre, was utilized for all patients. The quality
of haemodialysis was assessed by the urea reduction ratio,
which was >0.6 for all patients on all haemodialysis sessions,
with an average of 0.68±0.02. In addition, Kt/V [15] and the
protein equivalent of nitrogen appearance normalized per
bodyweight (nPNA) [16] were calculated for each patient for
one interdialytic period of all three trial phases. The mean
values were 1.34±0.09 for Kt/V and 1.20±0.09 g/kg/day for
nPNA.
Table 1. Characterization of the patients completing the study. Patients 1, 5, 7 and 8 were recruited for intra- and interdialysis kinetics (see
Table 2). All patients were treated with parenteral epoetin and iron preparations and oral calcitriol, multivitamin preparations and calcium
carbonate. Additional drugs for individual patients were acetylsalicylic acid, angiotensin-converting enzyme inhibitors and atorvastatin.
None of these drugs is known to interfere with carnitine metabolism
Patient Sex Age (years) Urine production
per day (ml)
Target weight
(kg)
Dialysis blood
ﬂow rate (l/min)
Carnitine dose
(mmol) for 10mg/kg
1 Female 46 0 59.0 0.30 3.66a
2 Male 75 200 83.5 NRb 5.17
3 Male 38 50 66.0 NR 4.08
4 Female 60 0 76.0 NR 4.69
5 Female 59 0 72.5c 0.30 4.39
6 Male 57 650 75.5 NR 4.69
7 Male 76 800 74.5 0.30 4.65
8 Female 58 0 62.0 0.30 3.83
aFor 20mg/kg the dose was doubled.
bNot relevant (NR), as patient did not participate in the intradialysis kinetic study.
c71.0 kg during the ﬁrst 2 weeks of the study.
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Study design
The study was performed over 7 weeks (21 haemodialysis
sessions) and included three different observation periods.
During the ﬁrst week, patients were studied under baseline
conditions (no carnitine supplementation; patients studied on
days 1 and 6). During the next 3 weeks, all patients were
supplemented after each dialysis session with 10mg/kg body
weight carnitine intravenously (low carnitine supplementa-
tion; patients studied on days 13, 20 and 27). During the last 3
weeks, carnitine supplementation was increased to 20mg/kg
body weight carnitine intravenously (high carnitine supple-
mentation; patients studied on days 34, 41 and 48). Carnitine
(Carnitene sigma-tau Sigma-Tau Pharma AG, Zoﬁngen,
Switzerland) was administered by injection over 2min
using the venous line installed for haemodialysis, just before
it was removed at the end of the haemodialysis session.
After the administration of carnitine, the line was ﬂushed
with saline. Blood samples were collected in 2ml heparinized
tubes, which were centrifuged and the plasma was removed
and stored in polystyrene tubes at 20C until analysis.
Carnitine and acylcarnitine proﬁles between
haemodialysis sessions
To establish the carnitine and acylcarnitine proﬁles over the
entire study period, blood collections were performed in all
patients twice under baseline conditions (before haemo-
dialysis sessions on days 1 and 6), thrice under low carnitine
supplementation (before haemodialysis sessions on days 13,
20 and 27) and thrice under high carnitine supplementation
(before haemodialysis sessions on days 34, 41 and 48).
Thus, the ﬁrst blood sample collections under the respective
supplementation conditions were performed after three and
the last after nine administrations of the respective carnitine
dosage. All samples were withdrawn immediately before the
respective haemodialysis session was started.
Carnitine and acylcarnitine kinetics during dialysis
sessions (intradialysis)
Intradialysis kinetics of carnitine was studied in four patients
(patients 1, 5, 7 and 8) under baseline conditions (session on
day 6), after 3 weeks of low carnitine supplementation
(session on day 27) and after 3 weeks of high carnitine
supplementation (session on day 48). Blood samples were
collected before haemodialysis was started, during and at the
end of haemodialysis just before the administration of
carnitine. During haemodialysis, arterial blood (blood enter-
ing in the dialysis system), venous blood (blood leaving the
dialysis system) and 10ml dialysate were collected at 10, 30,
60, 120, 180 and 240min after beginning haemodialysis. The
arterial blood was obtained just before the venous one and the
dialysate was collected just after the blood samples had been
obtained.
Carnitine and acylcarnitine kinetics between two
dialysis sessions (interdialysis)
Interdialysis kinetics of carnitine was studied in four patients
(patients 1, 5, 7 and 8) under baseline conditions (between
sessions on days 4 and 6) and at the end of the study (after
3 weeks of treatment with 20mg/kg carnitine; between
sessions on days 46 and 48). Blood samples were collected
before the start of haemodialysis, immediately after haemo-
dialysis and after the session on day 4, at 5, 10, 15, 20, 30 and
45min and 1, 2, 4, 6, 20 and 44 h after termination of
haemodialysis. After the session on day 46, a blood sample
was obtained, 20mg/kg carnitine was injected intravenously
over 2min and blood samples were obtained at the same time-
points as indicated above, beginning after termination of the
injection. At the end of haemodialysis, the venous line was
kept open during 6 h for the collection of blood. The 20 h
blood sample was obtained by venopuncture and the 44 h
collection time-point corresponded to the beginning of the
next haemodialysis session. Patients received a vegetarian
meal between the blood collections at 1 and 2 h.
Analysis of carnitine and acylcarnitines
Carnitine, the different acylcarnitines and butyrobetaine
present in plasma and dialysate samples were analysed by
LC–MS/MS according to a method published previously for
plasma [5]. Brieﬂy, samples were subjected to a solid-phase
extraction on a cation-exchange column and separation was
performed using a reversed-phase column in the presence of a
volatile ion-pairing reagent. Detection was carried out using
an ion-trap mass spectrometer run in the MS/MS mode.
The method linearity was 10–80mmol/l for carnitine and
0.5–20mmol/l for acetylcarnitine, propionylcarnitine, isova-
lerylcarnitine and butyrobetaine. Inter-day and intra-day
plasma quality controls (determined at the extremes of the
respective range of linearity) had precisions ranging from
2.2% to 13.7% and accuracies between 70.5% and 129.9%,
for both carnitine and acylcarnitines.
Plasma samples having high carnitine and acetylcarnitine
levels were diluted up to 40-fold with a 4% bovine serum
albumin solution in water before analysis in order to reach the
calibration range. Modiﬁed calibration ranges for carnitine
(5–60mmol/l) were used for the analysis of samples containing
a low carnitine concentration.
The acylcarnitine concentration used to calculate total
carnitine (sum of free and acylcarnitines) and the acylcarni-
tine to total carnitine ratios was obtained by summation of
the concentration of each individual acylcarnitine.
Statistics and pharmacokinetic analysis
Data are presented as means±SEM unless stated otherwise.
Kinetics of carnitine, acylcarnitine and butyrobetaine in the
interhaemodialysis period were analysed under baseline
conditions (between haemodialysis sessions on days 4 and 6)
and after 3 weeks of supplementation with 20mg/kg body
weight carnitine (between haemodialysis sessions on days 46
and 48). The area under the curve (AUC) from time 0 to 44 h
(AUC0–44) was determined with the linear trapezoidal rule
using TopFit software [17]. The baseline-corrected AUC was
calculated by subtracting the AUC obtained under baseline
conditions from the corresponding AUC after carnitine
substitution.
The intradialysis period was evaluated under baseline
conditions (haemodialysis session on day 6), after 3 weeks of
treatment with 10mg/kg body weight carnitine (haemo-
dialysis session on day 27) and after 3 weeks supplementation
with 20mg/kg body weight carnitine (haemodialysis session
452 L. Vernez et al.
on day 48). The extraction coefﬁcient (E) was calculated as
follows:
E ¼ ðCpre  CpostÞ=Cpre ð1Þ
where Cpre is the concentration of the analyte in arterial blood
plasma (entering the dialysis system) at the start of
haemodialysis and Cpost is the concentration in arterial
blood plasma at the end of haemodialysis. Alternatively, E
was calculated as:
E 0 ¼ ðCart  CvenÞ=Cart ð2Þ
where Cart is the arterial and Cven is the venous plasma
concentration at a given time-point. Since the values for E and
the average of E 0 (average of several determinations during
haemodialysis) were not different, E is given in Table 2 and
was used for the following calculations.
The clearance by haemodialysis was calculated as:
Clh ¼ Q E ð1 haematocritÞ ð3Þ
where Q is the haemodialysis blood ﬂow (Table 1) and E
is the extraction coefﬁcient (equation 1). The term
(1 haematocrit) was introduced due to the publication of
a study by Leschke et al. [12], showing that the carnitine
content of erythrocytes does not change signiﬁcantly during
haemodialysis. The haematocrit values obtained before
haemodialysis were used for the calculation (they were all in
the range of 0.30–0.35).
The amount of carnitine and acylcarnitines eliminated by
haemodialysis (Ah) was calculated as follows:
Ah ¼ AUCart; 0240  Clh ð4Þ
with AUCart; 0–240 being the AUC in arterial blood from time
zero until completion of haemodialysis after 240min.
Alternatively, the amount eliminated by haemodialysis was
calculated from the carnitine and acylcarnitine concentrations
in the dialysate:
Ad ¼ AUCd; 0240 Qd ð5Þ
with AUCd; 0–240 being the AUC in the dialysate calculated
using the trapezoidal rule and Qd the dialysate ﬂow
(0.5 l/min).
Results
Using a sensitive LC–MS/MS method, we investigated
the intra- and interdialysis kinetics of carnitine in
patients with chronic renal failure treated by haemo-
dialysis under baseline conditions and during treatment
with different amounts of intravenous carnitine. Under
baseline conditions, the plasma free carnitine concen-
trations ranged from 12.1 to 16.6 mmol/l. These levels
are in the same range as the 19.5±5.6 mmol/l reported
Table 2. Kinetics of carnitine, acylcarnitines and butyrobetaine during and between haemodialysis sessions. Values are expressed as
means±SEM, n¼ 4 patients. AUC reﬂects the area under the curve between two dialysis sessions (interdialysis) or within one session
(intradialysis). Clh represents the clearance by haemodialysis, E the extraction coefﬁcient by haemodialysis and Ah and Ad the amount of
carnitine or acylcarnitines removed by haemodialysis calculated using different methods. The calculation of these variables is described in
the ‘Subjects and methods’
Carnitine Acetylcarnitine Propionylcarnitine Butyrobetaine
Interdialysis
AUC0–44 h (mmol/l h)no substitution 540±18 200±13 NDa 45.0±4.3
AUC0–44 h (mmol/l h) 20mg/kg carnitine 9250±550 2690±200 242±23 108±10
Baseline-corrected AUC0–44 h (mmol/lh) 8710±550 2490±190 242±23 62.3±5.8
Intradialysis
No substitution
AUCart; 0–240min (mmol/lh) 24.7±1.9 7.59±0.75 ND 2.18±0.05b
Clh (l/h) 8.2±0.3 9.4±0.3 ND 8.3±0.6
b
E 0.65±0.02 0.75±0.02 ND 0.66±0.05b
Ah (mmol) 203±15 71.4±7.1 ND 18.2±1.8
b
Ad (mmol) 229±19 ND ND ND
10mg/kg carnitine
AUCart; 0–240min (mmol/lh) 64.4±2.4 25.1±0.5 3.03±0.12b 3.53±0.10
Clh (l/h) 10.0±0.58 10.4±0.3 9.89±0.22
b 9.67±0.25
E 0.76±0.03 0.80±0.03 0.79±0.02b 0.77±0.02
Ah (mmol) 640±15 262±11 30.0±1.9
b 34.1±1.3
Ad (mmol) 634±50 226±47 ND 32.0±4.0
b
Ah (% of carnitine administered)
c 23.8±1.1
20mg/kg carnitine
AUCart; 0–240min (mmol/lh) 197±25 88.9±17.0 4.96±0.16 3.45±0.31
Clh (l/h) 10.7±0.42 11.3±0.5 10.4±0.4 10.5±0.4
E 0.82±0.01 0.86±0.01 0.79±0.01 0.80±0.01
Ah (mmol) 2080±220 1030±250 51.4±1.5 35.9±2.4
Ad (mmol) 1950±230 915±162 ND 34.2±5.7
b
Ah (% of carnitine administered)
c 42.4±5.1
aNot determined (ND) (below the limit of quantiﬁcation).
bn¼ 2.
cIncludes carnitine, acetylcarnitine and propionylcarnitine.
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by Evans et al. [6] in similar patients, but lower as
compared with the 34.3±1.2 mmol/l obtained in healthy
persons [5]. The acylcarnitine to total carnitine
ratio was 0.30±0.02 (range: 0.22–0.39), a value
which is higher than the ratio of 0.16±0.02 observed
in healthy persons [5]. Acetylcarnitine was the most
prominent short-chain acylcarnitine, but propionyl-
carnitine was also detectable in ﬁve and isovaleryl-
carnitine in two patients. Other acylcarnitines were
not detectable. The carnitine precursor butyrobetaine
could be found in the plasma of all patients at a
concentration of 0.98±0.08 mmol/l (range: 0.61–1.38
mmol/l).
Carnitine and acylcarnitines proﬁles
The evolution of the pre-dialytic carnitine and acylcar-
nitine pools over the entire study is depicted in Figure 1.
After 1 week of supplementation with 10mg/kg
carnitine (low dosage) at the end of each haemodialysis
session, the carnitine pre-dialysis concentration
increased in all patients between 130% and 440% as
compared with baseline (mean plasma concentration:
40.2±5.3mmol/l; range: 21.1–70.8mmol/l). The acetyl-
carnitine concentration increased from 5.9±0.4 to
17.8±3.0mmol/l, propionylcarnitine from 0.7±0.1 to
1.20±0.2mmol/l and butyrobetaine from 0.94±0.09
to 1.83±0.17 mmol/l. After 3 weeks of low dosage
carnitine supplementation, the carnitine, acetylcarni-
tine and propionylcarnitine plasma levels had
increased further in most patients, while the isovaleryl-
carnitine and butyrobetaine levels remained constant.
After 1 week of carnitine supplementation at low
dosage, the acylcarnitine to total carnitine ratio had
reached a value of 0.31±0.02, which dropped to
0.29±0.01 at the end of the low carnitine supplementa-
tion period.
After 1 week of supplementation with 20mg/kg
carnitine (high dosage) at the end of each haemodialysis
session, the carnitine plasma concentration showed a
further increase to 114±17 mmol/l (range: 46.4–186
mmol/l). Similar to carnitine, acetylcarnitine increased
to 50.7±7.9mmol/l (range: 13.4–77.6mmol/l), propio-
nylcarnitine to 4.57±0.82 mmol/l (range: 1.23–8.58
mmol/l) and butyrobetaine to 2.69±0.36 mmol/l
(range: 1.56–4.21mmol/l). Isovalerylcarnitine appeared
in the plasma of ﬁve patients, reaching a concentration
of 0.75±0.04 mmol/l (range: 0.66–0.95 mmol/l). At the
end of the study, after 3 weeks of high-dose carnitine
supplementation, seven patients showed further
increases in their carnitine levels, reaching concentra-
tions of 78–229 mmol/l. In contrast, patient 4 showed a
constant carnitine plasma concentration of 47 mmol/l
over the entire 3 weeks of high-dose carnitine supple-
mentation. Further increases were also observed for
acetylcarnitine, propionylcarnitine and isovalerylcarni-
tine, reaching plasma concentrations of 69.0±11.9,
6.0±1.1 and 0.88±0.08 mmol/l, respectively. The mean
plasma concentration of butyrobetaine reached 2.58±
0.28mmol/l at the end of the high-supplementation
period. After 1 week of carnitine supplementation at
high dosage, the acylcarnitine to total carnitine ratio
had reached a value of 0.32±0.02, which increased to
0.34±0.01 at the end of the high carnitine supplemen-
tation period. The fact that the plasma carnitine
concentration tended to increase during the individual
supplementation periods (Figure 1) suggests that 3
weeks of carnitine supplementation were not sufﬁcient
for reaching steady-state conditions. This may be
explained by a slow turnover of carnitine in skeletal
muscle, which has been estimated to be in the range of
7–10 days [18].
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Fig. 1. Pre-dialysis plasma concentrations of carnitine, acylcarni-
tines and butyrobetaine. Values are expressed as means±SEM,
n¼ 8 patients. Analysis was performed by LC–MS/MS as described
in the ‘Subjects and methods’. Carnitine supplementation (intrave-
nous after each haemodialysis session) was as follows. Days 1 and
6: no supplementation (baseline); days 13, 20 and 27: 10mg/kg (low
carnitine supplementation); days 34, 41 and 48: 20mg/kg (high
carnitine supplementation).
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Intradialysis kinetics
The plasma concentration–time curves for carnitine,
acylcarnitines and butyrobetaine are given in Figure 2.
As known from previous studies [6,12], carnitine and
acetylcarnitine can be removed efﬁciently by haemo-
dialysis. As could be expected, this is also the case for
propionylcarnitine and butyrobetaine (Figure 2B and
2C). For carnitine, acylcarnitines and butyrobetaine,
apparent steady-state plasma concentrations are
reached after 2–3 h of haemodialysis. This apparent
steady-state concentration is 80% lower for all
analytes than the respective pre-dialysis plasma
concentrations, demonstrating efﬁcient removal by
haemodialysis.
The kinetic analysis of the plasma concentration–
time curves during haemodialysis allowed the cal-
culation of the extraction (E) by haemodialysis,
haemodialytic clearance (Clh) and the amount of
analytes removed by haemodialysis (Ah and Ad)
(Table 2). These calculations show that supplementa-
tion with increasing doses of carnitine is associated with
a dose-dependent removal of acyl groups by haemo-
dialysis. The good agreement between Ah and Ad
suggests that the equilibration between the carnitine
pool within the erythrocytes and plasma is minimal
during haemodialysis.
Interdialysis kinetics
At the end of haemodialysis, the plasma levels of all
analytes were reduced by 80% as compared with pre-
dialysis values (Figure 2). When carnitine was not
supplemented, carnitine, acetylcarnitine and butyro-
betaine plasma concentrations started to increase
already 5min after the end of haemodialysis
(Figure 3A). This increase was more marked during
the ﬁrst 6 h after haemodialysis and apparently stable
concentrations were reached after 8–24 h.
In patients supplemented with 20mg/kg carnitine,
the plasma carnitine concentration reached
1350±160 mmol/l 5min after termination of the intra-
venous administration of carnitine (Figure 3B). After
having reached the peak concentration, the plasma
carnitine concentration decreased with a half-life
of 2 h, attaining apparently stable concentrations
8–24 h after injection. After intravenous administration
of carnitine, the plasma concentrations of acetylcarni-
tine, propionylcarnitine and butyrobetaine increased
rapidly, reaching apparently stable concentrations after
8 h (Figure 3B). In patients 1 and 8, isovalerylcarnitine
was also detected and showed a similar kinetic
behaviour as the other acylcarnitines.
The AUCs for the interdialysis period obtained
without carnitine supplementation and after 3 weeks
of supplementation with 10 or 20mg/kg intravenous
carnitine are given in Table 2. In comparison to
baseline, the AUCs increased by a factor of 17.1±1.0
for carnitine, 13.5±1.0 for acetylcarnitine and 2.4±0.2
for butyrobetaine after supplementation with 20mg/kg
carnitine.
Discussion
Our study demonstrates that patients on long-term
haemodialysis have reduced plasma carnitine concen-
trations before and after haemodialysis, that carnitine,
acylcarnitines and butyrobetaine are removed efﬁ-
ciently by haemodialysis and that the plasma carnitine
and butyrobetaine levels can be increased to physiologi-
cal or even supraphysiological levels by supplementa-
tion of carnitine following each haemodialysis session.
Under baseline conditions, all patients investigated
were carnitine-deﬁcient with a mean plasma free
carnitine concentration of 15.1±0.6 mmol/l, which is
well below the concentration of 34.3±1.2 mmol/l found
in healthy persons [5]. The acylcarnitine to total
carnitine ratio was 0.30±0.02, indicating a redistribu-
tion of the plasma carnitine pool towards acylcarnitines
[5]. Acylcarnitines were represented mainly by
acetylcarnitine, as reported in other studies [6,7,14].
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Fig. 2. Kinetics of carnitine, acylcarnitines and butyrobetaine
during haemodialysis (intradialysis kinetics). Values are expressed
as means±SEM, n¼ 4 patients. Analysis was performed
by LC–MS/MS as described in the ‘Subjects and methods’.
(A) Baseline conditions (day 6). (B) During supplementation with
10mg/kg body weight carnitine (day 27). (C) During supplementa-
tion with 20mg/kg body weight carnitine (day 48). All analytes are
removed efﬁciently by haemodialysis, reaching a new apparent
steady state after 2 h.
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Interestingly, propionylcarnitine could be detected
in ﬁve patients with plasma concentrations ranging
between 0.52 and 0.81mmol/l. Propionylcarnitine has
also been detected in plasma of healthy persons, but at
lower concentrations as compared with the patients in
our study [19,20]. In addition, still under baseline
conditions, isovalerylcarnitine was present in two
patients at levels of 0.98 and 1.04mmol/l, also higher
concentrations than the 0.11±0.06 mmol/l reported in
healthy sportive subjects [19]. Since acylcarnitines are
formed from the respective acyl-CoAs [1], it can be
assumed that the tissue concentrations of propionyl-
CoA and isovaleryl-CoA are increased at least in some
patients on long-term haemodialysis. Depending on the
metabolic situation, the plasma carnitine proﬁle can
reﬂect both the carnitine pool of the liver [1,2] or of
skeletal muscle [3]. In the case of propionate, the
plasma carnitine proﬁle primarily reﬂects the liver
carnitine and coenzyme A pools, because propionate is
metabolized mainly by liver mitochondria [21]. It is well
known that propionate and other short- and medium-
chain fatty acids can impair mitochondrial function, in
particular mitochondrial b-oxidation [1,22]. This inhi-
bition may at least partially explain increased plasma
concentrations of free fatty acids in patients on long-
term haemodialysis [1,23] and suggests that removal of
short- and medium-chain acyl-groups may be poten-
tially beneﬁcial for this group of patients. Since the
administration of exogenous carnitine is associated not
only with an increase in free carnitine, but also in the
respective acylcarnitine fractions, and since acylcarni-
tines are removed efﬁciently by haemodialysis, carnitine
supplementation is indeed associated with an increased
removal of acyl groups by haemodialysis (Table 2). In
support of the hypothesis that carnitine may improve
mitochondrial metabolism in patients on long-term
haemodialysis, carnitine supplementation has been
associated with a drop in the plasma free fatty acid
concentration and with an increase in cardiac fatty acid
metabolism in this group of patients [1,23]. In addition,
beneﬁcial results on hepatic mitochondrial function
have also been reported in patients suffering from
methylmalonic aciduria, another condition with
hepatic accumulation of toxic acyl-CoAs, who were
treated with high doses of carnitine [2]. The adminis-
tration of carnitine to patients on long-term haemo-
dialysis may, therefore, act in at least two ways, namely
by increasing the low carnitine plasma and tissue levels
and by eliminating potentially toxic acyl-groups,
mainly from liver and possibly from other organs.
Butyrobetaine, the direct carnitine biosynthesis pre-
cursor [1,24], was present in all patients at concentra-
tions between 0.61 and 1.38mmol/l under baseline
conditions. These values are below reported mean
butyrobetaine plasma concentrations in healthy
persons of 1.80mmol/l determined by tandem mass
spectrometry [19] or 4.66 mmol/l determined by an
enzymatic assay [25]. Similar to carnitine, butyrobe-
taine is stored mainly in skeletal muscle [24]. In order to
be converted to carnitine, butyrobetaine has to be
transported out from skeletal muscle into the blood and
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Fig. 3. Kinetics of carnitine and acylcarnitines between two
haemodialysis sessions (interdialysis kinetics). Values are expressed
as means±SEM, n¼ 4 patients. Analysis was performed by
LC–MS/MS as described in the ‘Subjects and methods’. (A)
Baseline conditions between haemodialysis sessions on days 4 and 6
(no carnitine supplementation). (B) Supplementation with carnitine
(20mg/kg body weight) between haemodialysis sessions on days 46
and 48. The period between –4 and 0 h reﬂects the haemodialysis
session on day 4 (A) or on day 46 (B), respectively. The values at
44 h (pre-dialysis concentrations before haemodialysis sessions on
days 6 or 48, respectively) are not given in this ﬁgure, but can be
obtained from Figure 1. They do not differ signiﬁcantly from
the respective values obtained at –4 h. After a drop during
haemodialysis (see Figure 2 for details), the plasma carnitine,
acylcarnitine and butyrobetaine concentrations reach apparently
stable values 8–20 h after termination of haemodialysis.
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then into liver, kidney or testis, where butyrobetaine
hydroxylase is expressed and carnitine can be synthe-
sized [24]. Since butyrobetaine can be removed by
haemodialysis (Table 2 and Figure 2), patients on long-
term haemodialysis have lower butyrobetaine plasma
concentrations than healthy subjects. Considering that
butyrobetaine is taken up actively by tissues and that
the Km value of this transport is in the range of 5 mmol/l
[26], it can be assumed that transport into tissues shows
an almost linear relationship with the plasma concen-
trations, suggesting that patients on haemodialysis have
reduced tissue butyrobetaine concentrations. Impaired
carnitine biosynthesis may, therefore, contribute to the
low carnitine plasma and tissue concentrations [6–8] in
patients on long-term haemodialysis. In support of this
hypothesis, patients on long-term haemodialysis have
lower tissue concentrations of carnitine as compared
with healthy subjects, despite the fact that haemo-
dialysis removes less carnitine than renal excretion
in healthy subjects [12]. Our study therefore supports
the hypothesis that carnitine biosynthesis is reduced
in patients on long-term haemodialysis and offers a
possible mechanism for this assumption.
Interestingly, supplementation of carnitine in
patients on long-term haemodialysis is not only
associated with an increase in plasma carnitine and
acylcarnitines, but also in butyrobetaine (Figure 1). As
explained above, in order to be converted to carnitine,
butyrobetaine has to be transported out of skeletal
muscle and to be taken up by the kidney, liver or testis,
where it is hydroxylated to carnitine [24]. Since
butyrobetaine inhibits the transport of carnitine by
OCTN2 [27], an interaction between the transport of
carnitine and butyrobetaine into tissues could explain
our ﬁndings. An interaction on the level of the kidney
can be excluded in patients with end-stage renal disease,
but carnitine may inhibit the transport of butyrobetaine
into other tissues, e.g. testis and/or liver, where OCTN2
is expressed [27].
In conclusion, our study shows that carnitine, short-
chain acylcarnitines and butyrobetaine are removed
efﬁciently by haemodialysis and that supplementation
with exogenous carnitine increases the plasma concen-
trations of carnitine itself, but also of acylcarnitines and
butyrobetaine in patients on long-term haemodialysis.
Removal of potentially toxic acyl-groups as acylcarni-
tines by haemodialysis may explain some of the
beneﬁcial effects associated with the administration of
carnitine in this group of patients. The increase in the
plasma butyrobetaine concentration during carnitine
supplementation may be explained by an inhibition by
carnitine of the transport of butyrobetaine into tissues
such as testis and liver.
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